Cyanosis secondary prevention

Revision as of 06:01, 23 March 2018 by Medhat (talk | contribs)
Jump to navigation Jump to search

Cyanosis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyanosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cyanosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cyanosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyanosis secondary prevention

CDC on Cyanosis secondary prevention

Cyanosis secondary prevention in the news

Blogs on Cyanosis secondary prevention

Directions to Hospitals Treating Cyanosis

Risk calculators and risk factors for Cyanosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Secondary Prevention

Ultrasound follow-up
  • Serial assessment should be guided by the nature and severity of the lesion, presence of heart failure, anticipated timing and mechanism of progression, and the options available for prenatal and postpartum intervention. [14].
  • Assessment should be performed through infancy at 6- to 12-month intervals, and longer if abnormalities are present.
  • At least one follow-up examination early in the third trimester is reasonable in order to look for abnormalities that progressed in severity or may not have been detectable earlier in gestation, and have peripartum clinical implications.
  • This is also an appropriate time to screen for growth restriction, which may be more prevalent in these fetuses or specific subtypes of congenital heart disease [45-48].
  • All infants with severe PPHN who have been treated with inhaled nitric oxide (iNO) and/or extracorporeal membrane oxygenation (ECMO) should have neurodevelopmental follow-up [15].

References

Template:WH Template:WS